Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021–2022: an analysis of real-world data

OBJECTIVE: To evaluate utilization of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and angiotensin receptor neprilysin inhibitors (ARNi) in patients with atrial fibrillation (AF) and heart failure (HF). METHODS: We analyzed the MarketScan databases for the period 1/1/2021 to 6/30/2022. Validat...

Descripción completa

Detalles Bibliográficos
Autores principales: Alonso, Alvaro, Morris, Alanna A., Naimi, Ashley I., Alam, Aniqa B., Li, Linzi, Subramanya, Vinita, Chen, Lin Yee, Lutsey, Pamela L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508822/
https://www.ncbi.nlm.nih.gov/pubmed/37732232
http://dx.doi.org/10.1101/2023.09.08.23295280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508822/
https://www.ncbi.nlm.nih.gov/pubmed/37732232
http://dx.doi.org/10.1101/2023.09.08.23295280

Ejemplares similares